课题基金 / 基金详情

PRC Project--Butters

PRC Project--Butters
PRC项目--巴特斯
批准号：
8377366
负责人：
MERYL A BUTTERS
金额：
$18.91万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8377366
关键词：
AdherenceAdultAnxietyBiological MarkersBlood VesselsButterCaregiversChildChronicCognitiveCommunitiesCommunity NetworksComorbidityCompetenceDementiaDoctor of MedicineDoctor of PhilosophyEffectivenessElderlyEnrollmentFriendsGenotypeHormonesImpaired cognitionIncidenceIndividualInflammatoryInterventionLifeLinkMajor Depressive DisorderManualsMeasuresMediatingMedicalMental DepressionModelingNerve DegenerationOutcomePathologicPreventionProblem SolvingProceduresPsychosocial FactorRandomizedRiskRoleSiblingsSocial supportSpousesStagingStandardizationStressToxic effectTrainingcognitive functioncytokinegeriatric depressionimprovedinstrumental activity of daily livingmembermild neurocognitive impairmentneuroinflammationpreventprobandproblem solving therapystressortherapy developmenttreatment as usual

项目摘要

项目成果

MERYL A BUTTERS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mild cognitive impairment (MCI) is a transitional state between normal cognitive function and dementia. Depression frequently co-occurs with MCI and each increases the risk of developing the other.(192-196) Cognitive loss may act as a stressor (much like any chronic and potentially progressive medical illness), associated with a constellation of psychosocial factors that have been linked to increased depression risk.(197199) Once older adults develop major depression, multiple pathologic mechanisms (i.e., vascular, neurodegenerative, stress hormone toxicity(200-201) likely mediated by neuroinflammation, increase the risk of cognitive decline (in the case of depression risk of progression to dementia is doubled).(202)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Major Depression and Molecular Senescence: The Role of Sleep
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
3/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment resistant late-life depression
海外基金